Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.54 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | TGM2 | P21980 | 1/20 | 0.57 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.57 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | PLAU | P00749 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.50 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL614872 | 0.98 | LMNA (0.71) | LMNASMN1; SMN2HTTTGM2SLC1A3 | |
| (Chloromethyl)Benzene SCHEMBL28649859 | 0.91 | HTT (0.62) | LMNASMN1; SMN2HTTTGM2SLC1A3 | |
| Hydrochloric Acid SCHEMBL616935 | 0.90 | HTT (0.70) | LMNASMN1; SMN2HTTTGM2SLC1A3 | |
| SCHEMBL15671941 | 0.89 | HTT (0.64) | LMNASMN1; SMN2HTTTGM2SLC1A3 | |
| Hydrochloric Acid SCHEMBL5493238 | 0.89 | HTT (0.68) | LMNASMN1; SMN2HTTTGM2SLC1A3 | |
| Hydrochloric Acid SCHEMBL547893 | 0.89 | HTT (0.68) | LMNASMN1; SMN2HTTTGM2SLC1A3 | |
| SCHEMBL14486856 | 0.89 | HTT (0.64) | LMNASMN1; SMN2HTTTGM2SLC1A3 | |
| SCHEMBL615296 | 0.89 | HTT (0.72) | LMNASMN1; SMN2HTTTGM2SLC1A3 | |
| SCHEMBL25132908 | 0.88 | PRSS1 (0.59) | LMNASMN1; SMN2HTTTGM2SLC1A3 | |
| Hydrochloric Acid SCHEMBL4329921 | 0.88 | HTT (0.67) | LMNASMN1; SMN2HTTTGM2SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 407 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112961060-B | Isotope labeled N, N-dimethylethylenediamine, preparation method thereof and analysis method of short-chain fatty acid | 武汉大学 | 2022-03-25 | — | — | CN | claimed |
| CN-112961060-A | Isotope labeled N, N-dimethylethylenediamine, preparation method thereof and analysis method of short-chain fatty acid | 武汉大学 | 2021-06-15 | — | — | CN | claimed |
| EP-3364967-B1 | FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-4694981-A1 | HETEROCYCLIC COMPOUNDS AS DUAL INHIBITORS OF PD-L1 AND ADENOSINE RECEPTORS | Aurigene Oncology Limited (IN) | 2026-02-18 | — | — | EP | disclosed |
| US-20260014257-A1 | THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22 | CYTOKI PHARMA APS (DK) | 2026-01-15 | — | — | US | disclosed |
| US-20250360186-A1 | DOSAGE REGIMEN FOR INTERLEUKIN-22 DERIVATIVES | CYTOKI PHARMA APS (DK) | 2025-11-27 | — | — | US | disclosed |
| US-12466784-B2 | Analogs of pterostilbene amino acid bearing carbonates for treating a non-alcoholic fatty liver disease and nonalcoholic steatohepatitis | APICAL MOLECULAR BIOTECH CO., LTD. (TW) | 2025-11-11 | — | — | US | disclosed |
| US-12458706-B2 | Compounds and therapeutic uses thereof | AVVINITY THERAPEUTICS LIMITED (GB) | 2025-11-04 | — | — | US | disclosed |
| EP-4637803-A2 | DOSAGE REGIMEN FOR INTERLEUKIN-22 DERIVATIVES | Cytoki Pharma ApS (DK) | 2025-10-29 | — | — | EP | disclosed |
| EP-4136063-B1 | NOVEL ANALOGS OF PTEROSTILBENE AMINO ACID BEARING CARBONATES FOR TREATING A NON-ALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS | APICAL MOLECULAR BIOTECH CO LTD (TW) | 2025-10-22 | — | — | EP | disclosed |
| US-12447211-B2 | Therapeutic derivatives of interleukin-22 | CYTOKI PHARMA APS (DK) | 2025-10-21 | — | — | US | disclosed |
| EP-0715619-A4 | INHIBITORS OF TNF-ALPHA SECRETION | IMMUNEX CORP (US) | 1997-03-19 | — | — | EP | disclosed |
| US-5594106-A | Inhibitors of TNF-α secretion | IMMUNEX CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0721941-A1 | NOVEL COMPOUND HAVING PLATELET AGGREGATION INHIBITOR EFFECT | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1996-07-17 | — | — | EP | disclosed |
| EP-0715619-A1 | INHIBITORS OF TNF-ALPHA SECRETION | IMMUNEX CORPORATION (US) | 1996-06-12 | — | — | EP | disclosed |
| US-5482700-A | Substituted polyamino, polycarboxy complexing agent dimers for MRI and X-ray contrast | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-01-09 | — | — | US | disclosed |
| WO-1995006031-A1 | INHIBITORS OF TNF-ALPHA SECRETION | IMMUNEX CORPORATION (US) | 1995-03-02 | — | — | WO | disclosed |
| US-5275801-A | X-ray and magnetic resonance imaging of tumors | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-01-04 | — | — | US | disclosed |
| US-5126448-A | Anxiolytic agents, learning enhancement | ASAHI KASEI KOGYO K.K. (JP) | 1992-06-30 | — | — | US | disclosed |
| EP-0285671-A1 | PYRIDINE DERIVATIVES | Asahi Kasei Kabushiki Kaisha (JP) | 1988-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12458706-B2 | Compounds and therapeutic uses thereof | MAVS, NFATC1, MYD88 | CA2 4572/4885GAA 528/4885LMNA 3277/4885 |
| US-12447211-B2 | Therapeutic derivatives of interleukin-22 | IL2, IL2RA, IL23R | CA2 3742/4885GAA 3748/4885LMNA 4203/4885 |
| US-20250360186-A1 | DOSAGE REGIMEN FOR INTERLEUKIN-22 DERIVATIVES | IL2, FABP2, IL2RA | CA2 4204/4885GAA 2877/4885LMNA 4532/4885 |
| US-12466784-B2 | Analogs of pterostilbene amino acid bearing carbonates for treating a non-alcoholic fatty liver disease and nonalcoholic steatohepatitis | FABP1, GLS2, SLC1A5 | CA2 1131/4885GAA 2584/4885LMNA 1980/4885 |
| US-20260014257-A1 | THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22 | IL2, IL23R, IL36G | CA2 4103/4885GAA 4836/4885LMNA 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.